Mitigating the Risk of Transfusion-Transmitted Dengue in Australia

Table 3

Dengue endemicity and approaches used by blood operators for managing TT-DENV risk. Adapted from Teo et al., 2009 [31].

Country	Endemicity	Management approach
Australia	Nonendemic/episodic outbreaks in Queensland [6, 8]	(i) 4-week deferral for history of dengue infection [16]; (ii) 4-week deferral for persons returning from dengue affected areas [16]
Canada	Nonendemic	3-week travel-related deferral for travel outside of Canada, continental USA, or Europe [32]
Hong Kong	Nonendemic [33]	(i) 6-month deferral for history of dengue infection [31]; (ii) 2-week deferral for history of fever [31]; (iii) No travel-related deferral for dengue [31]
Netherlands	Nonendemic	(i) 2-week deferral for history of dengue infection [34]; (ii) 2-week deferral for history of fever [34]; (iii) 4-week travel-related deferral for donors returning from dengue risk areas [34]
New Zealand	Nonendemic	(i) 4-week deferral for history of dengue infection [35]; (ii) No travel-related deferral for dengue [35]
Puerto Rico	Endemic [36]	Pathogen inactivation (Intercept) recently implemented for use on plasma and platelet products [37]
Singapore	Endemic [38]	(i) 6-month deferral for history of dengue infection [31]; (ii) 3-week deferral for history of fever [31]; (iii) No travel-related deferral for dengue [31]
Sri Lanka	Endemic [39]	(i) No specific deferral for history of dengue infection [31]; (ii) 2-week deferral for history of fever [31]; (iii) No travel-related deferral for dengue [31]
United Kingdom	Nonendemic	(i) 2-week deferral for history of dengue infection [31]; (ii) No travel-related deferral for dengue [31]
United States of America	Nonendemic/episodic outbreaks in some states [8, 40]	(i) 4-week deferral for history of dengue infection [31]; (ii) No travel-related deferral for dengue [31]